spinal muscular atrophy
Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3
November 11, 2019Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy
Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy
July 2, 2019Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy
Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …
NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza
May 15, 2019Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …
Roche resigns itself to failure on SMA drug
June 1, 2018Medical Communications Roche, biotech, drugs, pharma, pharmaceutical, spinal muscular atrophy
Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …
EMA gives positive opinion on Biogen’s spinal muscular atrophy drug Spinraza
April 25, 2017Manufacturing and Production, Sales and Marketing Biogen, Ionis, Spinraza, spinal muscular atrophy
Biogen has revealed that Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA) , has received a positive opinion from …
Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint
November 7, 2016Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …
Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III
August 2, 2016Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy
Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …
Latest content
